US7141244B1
(en)
*
|
1992-03-02 |
2006-11-28 |
Chiron Srl |
Helicobacter pylori proteins useful for vaccines and diagnostics
|
GB2303855B
(en)
*
|
1994-07-01 |
1998-10-28 |
Rican Limited |
Helicobacter pylori antigenic protein preparation and immunoassays
|
ES2283012T3
(en)
*
|
1996-01-04 |
2007-10-16 |
Novartis Vaccines And Diagnostics, Inc. |
HELICOBACTER PYLORI BACTERIOFERRITINE.
|
AU5366099A
(en)
|
1998-08-20 |
2000-03-14 |
Connaught Laboratories Limited |
Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
|
US6686339B1
(en)
|
1998-08-20 |
2004-02-03 |
Aventis Pasteur Limited |
Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
|
EP1105489A1
(en)
|
1998-08-20 |
2001-06-13 |
Aventis Pasteur Limited |
Nucleic acid molecules encoding pomp91a protein of chlamydia
|
US6649370B1
(en)
|
1998-10-28 |
2003-11-18 |
Aventis Pasteur Limited |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
US6607730B1
(en)
|
1998-11-02 |
2003-08-19 |
Aventis Pasteur Limited/Aventis Pasteur Limitee |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
CA2353107A1
(en)
|
1998-12-01 |
2000-06-08 |
Andrew D. Murdin |
Chlamydia antigens and corresponding dna fragments and uses thereof
|
US20020061848A1
(en)
|
2000-07-20 |
2002-05-23 |
Ajay Bhatia |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
BR9916020A
(en)
|
1998-12-08 |
2002-01-22 |
Corixa Corp |
Compounds and methods for the treatment and diagnosis of chlamydia infection
|
GB9828000D0
(en)
|
1998-12-18 |
1999-02-10 |
Chiron Spa |
Antigens
|
US7297341B1
(en)
|
1998-12-23 |
2007-11-20 |
Sanofi Pasteur Limited |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
EP1140998B1
(en)
|
1998-12-28 |
2008-01-23 |
Aventis Pasteur Limited |
Chlamydia antigens and corresponding dna fragments and uses thereof
|
US6808713B1
(en)
|
1998-12-28 |
2004-10-26 |
Aventis Pasteur Limited |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
GB9902555D0
(en)
|
1999-02-05 |
1999-03-24 |
Neutec Pharma Plc |
Medicament
|
NZ514140A
(en)
|
1999-03-12 |
2001-09-28 |
Aventis Pasteur |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
ATE375391T1
(en)
|
1999-05-03 |
2007-10-15 |
Sanofi Pasteur Ltd |
CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND THEIR USES
|
JP4667694B2
(en)
|
1999-09-20 |
2011-04-13 |
サノフィ、パストゥール、リミテッド |
Chlamydia antigen and corresponding DNA fragments and uses thereof
|
US6632663B1
(en)
|
1999-09-22 |
2003-10-14 |
Aventis Pasteur Limited |
DNA immunization against chlamydia infection
|
JP4864264B2
(en)
|
1999-12-22 |
2012-02-01 |
サノフィ、パストゥール、リミテッド |
Chlamydia antigen and corresponding DNA fragments and uses thereof
|
AU2001239488B2
(en)
|
2000-02-28 |
2006-01-19 |
Glaxosmithkline Biologicals S.A. |
Heterologous expression of neisserial proteins
|
US20020071831A1
(en)
|
2000-04-04 |
2002-06-13 |
Murdin Andrew D. |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
US20020132994A1
(en)
*
|
2000-04-04 |
2002-09-19 |
Murdin Andrew D. |
Chlamydia antigens and corresponding DNA fragments and uses thereof
|
CA2407114A1
(en)
|
2000-04-21 |
2001-11-01 |
Corixa Corporation |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
CA2408199A1
(en)
|
2000-05-08 |
2001-11-15 |
Aventis Pasteur Limited |
Chlamydia antigens and corresponding dna fragments and uses thereof
|
EP1297005B1
(en)
|
2000-07-03 |
2009-08-26 |
Novartis Vaccines and Diagnostics S.r.l. |
Immunisation against chlamydia pneumoniae
|
GB0024200D0
(en)
*
|
2000-10-03 |
2000-11-15 |
Smithkline Beecham Sa |
Component vaccine
|
US20030059896A1
(en)
*
|
2000-12-21 |
2003-03-27 |
Shire Biochem Inc. |
Novel chlamydia antigens and corresponding DNA fragments
|
US7082569B2
(en)
|
2001-01-17 |
2006-07-25 |
Outlooksoft Corporation |
Systems and methods providing dynamic spreadsheet functionality
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
ES2240745T3
(en)
*
|
2001-06-05 |
2005-10-16 |
Curevac Gmbh |
PHARMACEUTICAL COMPOSITION CONTAINING A STABILIZED AND OPTIMIZED mRNA FOR TRANSLATION, APPROPRIATE AS A VACCINE AND AS A REGENERANT OF FABRICS.
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
WO2003018054A1
(en)
*
|
2001-08-31 |
2003-03-06 |
Chiron Srl. |
Helicobacter pylori vaccination
|
ES2312649T3
(en)
|
2001-12-12 |
2009-03-01 |
Novartis Vaccines And Diagnostics S.R.L. |
IMMUNIZATION AGAINST CHLAMYDIA TRACHOMATIS.
|
DE10162480A1
(en)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
The application of mRNA for use as a therapeutic agent against tumor diseases
|
WO2003059381A2
(en)
*
|
2002-01-18 |
2003-07-24 |
Curevac Gmbh |
Immunogenic preparations and vaccines on the basis of mrna
|
GB0203403D0
(en)
|
2002-02-13 |
2002-04-03 |
Chiron Spa |
Chlamydia cytotoxic-T cell epitopes
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
EP1556477B1
(en)
|
2002-11-01 |
2017-08-09 |
GlaxoSmithKline Biologicals s.a. |
Drying process
|
WO2004046177A2
(en)
|
2002-11-15 |
2004-06-03 |
Chiron Srl |
Unexpected surface proteins in neisseria meningitidis
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
WO2004087153A2
(en)
|
2003-03-28 |
2004-10-14 |
Chiron Corporation |
Use of organic compounds for immunopotentiation
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
ES2596553T3
(en)
|
2003-06-02 |
2017-01-10 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions based on microparticles comprising adsorbed toxoid and an antigen containing a polysaccharide
|
CA2534502C
(en)
*
|
2003-08-19 |
2011-12-20 |
Shell Canada Limited |
Drilling system and method
|
CN1906299A
(en)
*
|
2003-11-21 |
2007-01-31 |
圣诺菲·帕斯图尔有限公司 |
Immunization against chlamydia infection
|
EP1729800A4
(en)
*
|
2004-03-02 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Immunogenic compositions for chlamydia pneunomiae
|
CA2571710A1
(en)
|
2004-06-24 |
2006-11-02 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
WO2006078318A2
(en)
|
2004-07-29 |
2006-07-27 |
Novartis Vaccines And Diagnostics Inc. |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
DE102004042546A1
(en)
*
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Combination therapy for immune stimulation
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
GB0502096D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Purification of streptococcal capsular polysaccharide
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
HUE027400T2
(en)
|
2005-02-18 |
2016-10-28 |
Glaxosmithkline Biologicals Sa |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
NZ580974A
(en)
|
2005-02-18 |
2011-05-27 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic escherichia coli
|
US20110223197A1
(en)
|
2005-10-18 |
2011-09-15 |
Novartis Vaccines And Diagnostics Inc. |
Mucosal and Systemic Immunization with Alphavirus Replicon Particles
|
US7527801B2
(en)
|
2005-11-22 |
2009-05-05 |
Novartis Vaccines And Diagnostics, Inc. |
Norovirus and Sapovirus antigens
|
EP2368570A3
(en)
|
2006-01-18 |
2012-05-02 |
University Of Chicago |
Compositions and methods related to staphylococcal bacterium proteins
|
ES2536426T3
(en)
|
2006-03-23 |
2015-05-25 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
AU2007248476B2
(en)
*
|
2006-05-05 |
2012-09-06 |
Perkinelmer Las, Inc |
Quantitative analysis of surface-derived samples using mass spectrometry
|
US20100166788A1
(en)
|
2006-08-16 |
2010-07-01 |
Novartis Vaccines And Diagnostics |
Immunogens from uropathogenic escherichia coli
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
KR101621837B1
(en)
|
2007-09-12 |
2016-05-17 |
노파르티스 아게 |
Gas57 mutant antigens and gas57 antibodies
|
DK2235046T3
(en)
|
2007-12-21 |
2012-10-29 |
Novartis Ag |
Mutant forms of streptolysin-O
|
US8466167B2
(en)
|
2008-03-03 |
2013-06-18 |
Irm Llc |
Compounds and compositions as TLR activity modulators
|
JP2012502972A
(en)
|
2008-09-18 |
2012-02-02 |
ノバルティス アーゲー |
Combination of vaccine adjuvant
|
ES2586308T3
(en)
|
2008-10-27 |
2016-10-13 |
Glaxosmithkline Biologicals Sa |
Purification procedure of a group A Streptococcus carbohydrate
|
US8585505B2
(en)
|
2008-12-15 |
2013-11-19 |
Tetris Online, Inc. |
Inter-game interactive hybrid asynchronous computer game infrastructure
|
WO2010078556A1
(en)
|
2009-01-05 |
2010-07-08 |
Epitogenesis Inc. |
Adjuvant compositions and methods of use
|
AU2010204139A1
(en)
|
2009-01-12 |
2011-08-11 |
Novartis Ag |
Cna_B domain antigens in vaccines against gram positive bacteria
|
RU2011140508A
(en)
|
2009-03-06 |
2013-04-20 |
Новартис Аг |
Chlamydia antigens
|
ITMI20090946A1
(en)
|
2009-05-28 |
2010-11-29 |
Novartis Ag |
EXPRESSION OF RECOMBINANT PROTEINS
|
EP2440245B1
(en)
|
2009-06-10 |
2017-12-06 |
GlaxoSmithKline Biologicals SA |
Benzonaphthyridine-containing vaccines
|
ES2596653T3
(en)
|
2009-06-16 |
2017-01-11 |
Glaxosmithkline Biologicals Sa |
Opsonization bactericidal and antibody-dependent assays mediated by high-performance complement
|
AU2010288239B2
(en)
|
2009-08-27 |
2014-01-16 |
Novartis Ag |
Adjuvant comprising aluminium, oligonucleotide and polycation
|
JO3257B1
(en)
|
2009-09-02 |
2018-09-16 |
Novartis Ag |
Compounds and compositions as tlr activity modulators
|
US9950062B2
(en)
|
2009-09-02 |
2018-04-24 |
Glaxosmithkline Biologicals Sa |
Compounds and compositions as TLR activity modulators
|
BR112012009014B8
(en)
|
2009-09-30 |
2022-10-04 |
Novartis Ag |
PROCESS FOR PREPARING S. AUREUS CAPSULAR POLYSACCHARIDE CONJUGATE TYPE 5 OR TYPE 8 AND CRM197 TRANSPORT MOLECULE, CONJUGATE AND IMMUNOGENIC COMPOSITION
|
RU2579900C2
(en)
|
2009-10-30 |
2016-04-10 |
Новартис Аг |
Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
|
WO2011057148A1
(en)
|
2009-11-05 |
2011-05-12 |
Irm Llc |
Compounds and compositions as tlr-7 activity modulators
|
SG181712A1
(en)
|
2009-12-15 |
2012-07-30 |
Novartis Ag |
Homogeneous suspension of immunopotentiating compounds and uses thereof
|
JP5848748B2
(en)
|
2010-03-23 |
2016-01-27 |
アイアールエム・リミテッド・ライアビリティ・カンパニーIrm,Llc |
Compounds (cysteine-based lipopeptides) and compositions as TLR2 agonists for use in the treatment of infectious diseases, inflammation, respiratory diseases, etc.
|
WO2011133433A2
(en)
*
|
2010-04-16 |
2011-10-27 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention |
Real time pcr assay for detection of bacterial respiratory pathogens
|
JP5940064B2
(en)
|
2010-07-06 |
2016-06-29 |
ノバルティス アーゲー |
Immunization of large mammals with low doses of RNA
|
HUE047796T2
(en)
|
2010-07-06 |
2020-05-28 |
Glaxosmithkline Biologicals Sa |
Delivery of rna to trigger multiple immune pathways
|
MX2013000164A
(en)
|
2010-07-06 |
2013-03-05 |
Novartis Ag |
Liposomes with lipids having an advantageous pka- value for rna delivery.
|
US9770463B2
(en)
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
JP6061849B2
(en)
|
2010-07-06 |
2017-01-18 |
ノバルティス アーゲー |
Virion-like delivery particles for self-replicating RNA molecules
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
EP2600901B1
(en)
|
2010-08-06 |
2019-03-27 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
CA2809851A1
(en)
|
2010-08-31 |
2012-03-08 |
Novartis Ag |
Pegylated liposomes for delivery of immunogen-encoding rna
|
AU2011295938B2
(en)
|
2010-08-31 |
2016-01-14 |
Glaxosmithkline Biologicals S.A. |
Lipids suitable for liposomal delivery of protein-coding RNA
|
WO2012031140A1
(en)
|
2010-09-01 |
2012-03-08 |
Novartis Ag |
Adsorption of immunopotentiators to insoluble metal salts
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
US20120237975A1
(en)
|
2010-10-01 |
2012-09-20 |
Jason Schrum |
Engineered nucleic acids and methods of use thereof
|
EP4098324A1
(en)
|
2010-10-11 |
2022-12-07 |
GlaxoSmithKline Biologicals S.A. |
Antigen delivery platforms
|
WO2012082914A1
(en)
|
2010-12-14 |
2012-06-21 |
Novartis Ag |
Flow cytometry analysis of materials adsorbed to metal salts
|
US20130315959A1
(en)
|
2010-12-24 |
2013-11-28 |
Novartis Ag |
Compounds
|
EP2667852B1
(en)
|
2011-01-27 |
2016-11-09 |
GlaxoSmithKline Biologicals SA |
Adjuvant nanoemulsions with crystallisation inhibitors
|
JP6191082B2
(en)
|
2011-03-02 |
2017-09-06 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
Combination vaccine with lower dose of antigen and / or adjuvant
|
ES2785108T3
(en)
|
2011-03-24 |
2020-10-05 |
Glaxosmithkline Biologicals Sa |
Adjuvant nanoemulsions with phospholipids
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
PL2710033T3
(en)
|
2011-05-17 |
2021-10-25 |
The Rockefeller University |
Human immunodeficiency virus neutralizing antibodies and methods of use thereof
|
CN107837394A
(en)
*
|
2011-06-24 |
2018-03-27 |
埃皮托吉尼西斯有限公司 |
Pharmaceutical composition as the combination of the carrier comprising selection of antigen specific immune conditioning agent, vitamin, tannin and flavonoids
|
EP2729126B1
(en)
|
2011-07-06 |
2020-12-23 |
GlaxoSmithKline Biologicals SA |
Liposomes having useful n:p ratio for delivery of rna molecules
|
JP2014522842A
(en)
|
2011-07-06 |
2014-09-08 |
ノバルティス アーゲー |
Immunogenic combination compositions and uses thereof
|
SI2750707T1
(en)
|
2011-08-31 |
2019-02-28 |
Glaxosmithkline Biologicals Sa |
Pegylated liposomes for delivery of immunogen-encoding rna
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
EP2755683B1
(en)
|
2011-09-14 |
2019-04-03 |
GlaxoSmithKline Biologicals SA |
Methods for making saccharide-protein glycoconjugates
|
RS62993B1
(en)
|
2011-10-03 |
2022-03-31 |
Modernatx Inc |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
EP2776069A1
(en)
|
2011-11-07 |
2014-09-17 |
Novartis AG |
Carrier molecule comprising a spr0096 and a spr2021 antigen
|
WO2013090648A1
(en)
|
2011-12-16 |
2013-06-20 |
modeRNA Therapeutics |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
JP2015510872A
(en)
|
2012-03-07 |
2015-04-13 |
ノバルティス アーゲー |
Enhanced formulation of Streptococcus pneumoniae antigen
|
PL2822947T3
(en)
|
2012-03-07 |
2017-01-31 |
Glaxosmithkline Biologicals Sa |
Arginine salts of a tlr7 agonist
|
MX2014010417A
(en)
|
2012-03-08 |
2014-09-22 |
Novartis Ag |
Adjuvanted formulations of booster vaccines.
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
EP3501550A1
(en)
|
2012-04-02 |
2019-06-26 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins associated with human disease
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
KR20150021933A
(en)
|
2012-05-22 |
2015-03-03 |
노파르티스 아게 |
Meningococcus serogroup x conjugate
|
RU2662970C2
(en)
|
2012-09-18 |
2018-07-31 |
Новартис Аг |
Outer membrane vesicles
|
SI2922554T1
(en)
|
2012-11-26 |
2022-06-30 |
Modernatx, Inc. |
Terminally modified rna
|
CA2899787A1
(en)
|
2013-02-01 |
2014-08-07 |
Glaxosmithkline Biologicals Sa |
Intradermal delivery of immunological compositions comprising toll-like receptor agonists
|
EA030650B1
(en)
|
2013-03-08 |
2018-09-28 |
Новартис Аг |
Lipids and lipid compositions for the delivery of active agents
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
US10323076B2
(en)
|
2013-10-03 |
2019-06-18 |
Modernatx, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
ES2806575T3
(en)
|
2013-11-01 |
2021-02-18 |
Curevac Ag |
Modified RNA with decreased immunostimulatory properties
|
US10059655B2
(en)
|
2013-12-19 |
2018-08-28 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
WO2015095346A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
EP3169309B1
(en)
|
2014-07-16 |
2023-05-10 |
Novartis AG |
Method of encapsulating a nucleic acid in a lipid nanoparticle host
|
JP6731912B2
(en)
|
2014-09-05 |
2020-07-29 |
ノバルティス アーゲー |
Lipids and lipid compositions for delivery of active substances
|
EP3061826A1
(en)
|
2015-02-27 |
2016-08-31 |
Novartis AG |
Flavivirus replicons
|
TW201718638A
(en)
|
2015-07-21 |
2017-06-01 |
現代治療公司 |
Infectious disease vaccines
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
Tropical disease vaccines
|
CN108367058A
(en)
*
|
2015-11-10 |
2018-08-03 |
俄亥俄州创新基金会 |
With the relevant method and composition of body fluid affinity of quickening
|
US11612664B2
(en)
|
2016-04-05 |
2023-03-28 |
Gsk Vaccines S.R.L. |
Immunogenic compositions
|
US10653767B2
(en)
|
2017-09-14 |
2020-05-19 |
Modernatx, Inc. |
Zika virus MRNA vaccines
|
KR20200123436A
(en)
|
2018-02-12 |
2020-10-29 |
이니뮨 코퍼레이션 |
Toll-like receptor ligand
|
WO2022096590A1
(en)
|
2020-11-04 |
2022-05-12 |
Eligo Bioscience |
Phage-derived particles for in situ delivery of dna payload into c. acnes population
|
WO2023021427A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
|
WO2023021421A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Low-dose lyophilized rna vaccines and methods for preparing and using the same
|